Expanded Access of Sotorasib
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04667234 |
|
Expanded Access Status :
No longer available
First Posted : December 14, 2020
Last Update Posted : September 28, 2023
|
Sponsor:
Amgen
Information provided by (Responsible Party):
Amgen
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
| Tracking Information | ||||
|---|---|---|---|---|
| First Submitted Date | December 8, 2020 | |||
| First Posted Date | December 14, 2020 | |||
| Last Update Posted Date | September 28, 2023 | |||
| Descriptive Information | ||||
| Brief Title | Expanded Access of Sotorasib | |||
| Brief Summary | The primary objective of this study is to provide expanded access to and characterize the safety profile of Sotorasib in participants with previously treated locally advanced/unresectable/metastatic non small-cell lung cancer (NSCLC) with KRAS p.G12C mutation in a real-world setting. | |||
| Detailed Description | Not Provided | |||
| Study Type | Expanded Access | |||
| Expanded Access Type | Treatment IND/Protocol | |||
| Intervention | Drug: AMG 510
Administered as an oral tablet.
Other Names:
|
|||
| Publications * | Not Provided | |||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
| Recruitment Information | ||||
| Expanded Access Status | No longer available | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Argentina, Brazil, Israel, Saudi Arabia, Taiwan, United States | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT04667234 | |||
| Current Responsible Party | Amgen | |||
| Original Responsible Party | Same as current | |||
| Current Study Sponsor | Amgen | |||
| Original Study Sponsor | Same as current | |||
| Collaborators | Not Provided | |||
| Investigators |
|
|||
| PRS Account | Amgen | |||
| Verification Date | September 2023 | |||